Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly shy of expectations, top-line revenue growth was a significant beat.

Get a deeper insight into the potential performance of Vertex (VERX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates ...

were trading largely flat post-market Monday after the biotech company released its Q4 earnings report and issued 2025 guidance that was largely in line with Street expectations. For Q4, Vertex ...

Increased adoption of Vertex’s tax automation solution is likely to have expanded its client roster and improved its top-line growth. VERX’s transition to cloud-based solutions is likely to ...

The drugmaker is looking to its acute pain drug, Journavx, to drive growth beyond its established line of cystic fibrosis treatments. Vertex expects to begin shipping Journavx to pharmacies in the ...